OBJECTIVES: Genome-wide association studies (GWAS) have identified loci reproducibly associated with inflammatory bowel disease (IBD) and other immune-mediated diseases; however, the molecular mechanisms underlying most of genetic susceptibility remain undefined. Expressional quantitative trait loci (eQTL) of disease-relevant tissue can be employed in order to elucidate the genes and pathways affected by disease-specific genetic variance. METHODS: In this study, we derived eQTLs for human whole blood and intestine tissues of anti-tumor necrosis factor-resistant Crohn's disease (CD) patients. We interpreted these eQTLs in the context of published IBD GWAS hits to inform on the disease process. RESULTS: At 10% false discovery rate, we discovered that 5,174 genes in blood and 2,063 genes in the intestine were controlled by a nearby single-nucleotide polymorphism (SNP) (i.e., cis-eQTL), among which 1,360 were shared between the two tissues. A large fraction of the identified eQTLs were supported by the regulomeDB database, showing that the eQTLs reside in regulatory elements (odds ratio; OR = 3.44 and 3.24 for blood and intestine eQTLs, respectively) as opposed to protein-coding regions. Published IBD GWAS hits as a whole were enriched for blood and intestine eQTLs (OR = 2.88 and 2.05; and P value = 2.51E-9 and 0.013, respectively), thereby linking genetic susceptibility to control of gene expression in these tissues. Through a systematic search, we used eQTL data to inform 109 out of 372 IBD GWAS SNPs documented in National Human Genome Research Institute catalog, and we categorized the genes influenced by eQTLs according to their functions. Many of these genes have experimentally validated roles in specific cell types contributing to intestinal inflammation. CONCLUSIONS: The blood and intestine eQTLs described in this study represent a powerful tool to link GWAS loci to a regulatory function and thus elucidate the mechanisms underlying the genetic loci associated with IBD and related conditions. Overall, our eQTL discovery approach empirically identifies the disease-associated variants including their impact on the direction and extent of expression changes in the context of disease-relevant cellular pathways in order to infer the functional outcome of this aspect of genetic susceptibility.
INTRODUCTION
Translational impact. The majority of IBD genetic loci identified by GWAS resides in the non-coding region and is thought to have regulatory roles. Discovering the functional outcome of these regulatory variations is integral to understanding IBD susceptibility. In this report, we identify shared and unique eQTLs in the two key tissues of IBD the blood and intestine, which were assessed in the same set of CD patients. These eQTLs pinpoint the association between IBD genetic loci and the downstream genes under influence, as well as their magnitude and direction of genetic effect (ie., does the disease risk allele up-or downregulate downstream genes). Alongside the deeper understanding of the context of IBD susceptibility, eQTLs also provide guidance in designing new therapeutic treatments. In this way, eQTLs, either as protective or pathogenic variants, directly or indirectly could be candidates for further consideration as drug targets. EQTLs may also be predictive of drug response, as reported in other disease studies, [1] [2] [3] and might inform on mechanistic insight in drug response. For example, the disease allele of rs4728142 upregulates certain transcripts of IRF5 gene in both the blood and the intestine among CD patients. IRF5 has also been described as leading to late phase TNFα secretion in human dendritic cells. 4 Therefore, this genetic polymorphism (rs4728142) may have a role in affecting anti-TNF response. These types of data aid future precision medicine efforts that will ultimately include optimized models based on scoring an individual's cumulative genetic risk to predict downstream molecular level changes, disease progression and drug response.
Inflammatory bowel disease (IBD) is comprised of two different disease sub-types, Crohn's disease (CD) and ulcerative colitis, which are distinguished by specific clinical and pathological features. Inflammation in Crohn's is patchy, affecting the distal ileum and/or colon with peri anal involvement; whereas in ulcerative colitis, inflammation manifests in a continuous manner from the rectum toward the proximal region of the colon. Crohn's disease is characterized by transmural inflammation, whereas the inflammation in ulcerative colitis is confined to the mucosa. IBD can be initiated by an environmental trigger in a genetically susceptible individual altering immune homeostasis in the intestinal mucosa, often resulting in compromised intestinal function. 5 Lack of resolution of inflammation in response to an infectious or inflammatory trigger can lead to chronic intestinal inflammation and tissue damage further compromising barrier function.
Understanding the genetic and environmental interaction in the intestine is critical in uncovering the basis for IBD onset, progression, and remission. 5 Many of the most significant genome-wide association study (GWAS) hits are at loci with unknown function and extensive linkage disequilibrium within many of these associated loci make it difficult to identify the causal susceptibility variant, let alone which genes they influence. Integrative genomics is a promising new approach to identify true causal genes and variants, with improved statistical power. The known associated polymorphisms can only explain a relatively small proportion of the variability of the IBD risk in human populations. 6 A component of this so-called missing heritability could be due to the limited power of GWAS as these studies may miss disease susceptibility singlenucleotide polymorphisms (SNPs) that are of small-tomoderate effect size. Interestingly, most of these SNPs are not in protein-coding regions, meaning they are less likely to impact protein function per se. In fact, the majority of this genetic contribution to disease is thought to come from expression quantitative trait loci (eQTL) or in other words, genomic loci that contribute to variation in the expression levels of mRNAs. An eQTL is the genetic polymorphism whose genotype is significantly associated with an mRNA's expression level, and that genetic polymorphism that in most cases is a SNP is in turn called an expression SNP or eSNP. An important distinction is made as to the location of the eQTL relative to the physical location of the gene whose expression level it is associated to. If the eQTL is close to the gene (which codes the mRNA), it is defined as a cis-eQTL. In contrast, if the eQTL is distant (typically 4500 kb away or on another chromosome altogether) from the gene, it is defined as a transeQTL. In the current paper, we also applied this definition. A ciseQTL is usually stronger (of larger genetic effect size) than trans-eQTLs. Also, the number of tests performed in discovering cis-eQTLs is much less than for trans-eQTLs because given the nature of the definition we only search the chromosome region approximate to a gene to discover cis-eQTLs but search the entire genome for trans-eQTLs. The heavier multiple testing burden means studies inherently have lower statistical power in detecting trans-eQTL, and in fact, eQTL studies routinely define significantly more cis-eQTLs than trans-eQTLs. [7] [8] [9] The outcome of any GWA study of a case and control design is a statistical association between a region of the genome (of a certain size) and the disease of interest. This means, GWAS do not reveal the tissue, organ or cell type where the associated SNPs are functional or how they may modify disease risk. One way to capture this information is via integration with eQTL analysis. EQTL is a powerful approach that empirically links the GWAS SNPs to pathologically relevant genes expressed in a tissue of interest. In this study the blood and intestine were studied given the importance of these tissues in IBD disease biology. By using gene expression as a phenotype and examining how DNA polymorphisms contribute to both gene expression and disease phenotype, true causal relationships can be dissected. [10] [11] [12] Although many eQTLs are conserved across tissues the impact of the polymorphism on the extent and direction of change in expression may be tissue specific. Thus, by capturing the direction of modulation specific to intestine and blood eQTLs and then linking this to variants with associated IBD disease risk, one can infer in a disease tissue context the impact of the genetic variation. Given this rationale, we systematically profiled the transcriptome of intestine and blood tissue collected from a previously described cohort of anti-tumor necrosis factor (TNF) refractory Crohn's patients, 13 and identified eQTLs both conserved and specific to blood and intestine. Importantly, these eQTLs were mined alongside other disease GWAS hits including more general IBD as well as canonical biological pathway databases, enabling us to provide a framework to understand the nature of the IBDassociated eQTLs from the blood and intestine of this anti-TNF refractory IBD patient cohort. 9, 12, 14 
METHODS
Dataset. Blood and biopsy data were collected at baseline from anti-TNF resistant Crohn's disease (CD) patients enrolled in the Ustekinumab trial previously described. 15 All patients met the criteria of a primary nonresponse, a secondary nonresponse, or unacceptable side-effects after receiving a TNF antagonist at an approved dose. Patients were permitted to continue receiving stable doses of drugs for the treatment of CD, including oral prednisolone (≤40 mg/day) or budesonide (≤9 mg/day), immunomodulators (e.g., azathioprine, mercaptopurine, or methotrexate), mesalamine, and antibiotics, if they had been taking the drugs for at least the pre-specified period before study entry of 3 weeks, 4 weeks, 3 weeks, and 3 weeks, respectively. Patients had not received previous therapies specifically targeting interleukin-12 or interleukin-23. Previous treatment with intravenous glucocorticoids, TNF antagonists, or natalizumab was not permitted for the pre-specified washout periods of 3 weeks, 8 weeks, and 12 months, respectively. 15 Two 2.5 ml blood samples were collected at the trial baseline using PAXgene tubes from all subjects (1,528 blood samples in total). All blood samples were stored at − 80°C until RNA isolation was performed. A subset of 150 blood samples was hybridized by microarray for genome-wide mRNA expression profiling. Ileal, rectal, and colonic biopsies were collected at the screening visits from a sub-group of subjects who consented to this procedure. Biopsies were obtained from selected colonic sections, including the ascending, transverse, and descending colonic regions, and from both inflamed and non-involved areas. The inflamed regions were defined as the colonic segments with the most severe disease activity. Additional biopsies were collected from the terminal ileum and from the rectum (i.e., the distal 10 cm of the colon).
Total RNA including micro ribonucleic acids was isolated with PAXgene Blood RNA MDx Kit plus customized reagent BM3 (Qiagen Inc., Valencia, CA, USA). RNA quantity and quality were determined with a LabChip GX (Caliper Life Sciences, Hopkinton, MA, USA). Gene expression were carried out using Affymetrix GeneChip HTHGU133+ (Affymetrix, Santa Clara, CA, USA Cat# 901262) according to the manufacturer's protocol with the exception that dimethyl sulphoxide replaced the Tetramethylammonium Chloride Solution in the hybridization buffer. Arrays were washed and stained on the Affymetrix GeneChip Array Station then scanned on an HTAPS scanner. Genotyping was performed at the Medical Genetics Institute as Cedars-Sinai Medical Center using Illumina OmniExpress chips (Human610-Quadv1 Chips; Illumina, San Diego, CA, USA). Genotypes were determined based on clustering of the raw intensity data for the two dyes using Illumina BeadStudio software. Six samples performed in duplicate yielded 499% concordance. In total, 733,120 SNPs were successfully genotyped.
Data analysis workflow. In Figure 1a and Figure 1b we report a schematic of the data analysis workflow and subsequent eQTL results mining, respectively. In brief, after quality control filtering of the data, we collected blood and intestine biopsies from 152 anti-TNF-resistant IBD patients. Gene expression was quantified by microarray on all samples, whereas blood samples were used for genotyping. Genotype and gene expression data, separately for blood and intestine, were then used for eQTL mapping. One the two eQTL sets were computed, we applied several data mining techniques to facilitate interpretation of the results in the context of disease including: testing for whether eQTLs (blood and intestine) were enriched for disease GWAS loci, overlap with known CD and IBD risk loci, Ingenuity Pathway Analysis and cell type enrichment analysis. Details about data QC, eQTL mapping and downstream mining of results are reported in the Supplementary Methods section.
RESULTS
Discovery of new eQTLs in blood and intestine. Discovery of eQTLs were based on genetic and microarray gene expression profiles collected from a cohort of anti-TNFresistant CD patients. 15 In all, 149 blood samples (all from unique subjects) and 203 intestine specimens from 54 unique subjects were employed. The demographic statistics were summarized in Supplementary Table S1 . Given that the 203 intestine samples were not all from unique subjects, we applied a mixed effect model to address the inherent correlation structure arising from testing multiple biopsies of the same subject. At 10% false discovery rate, we mapped 10 706 unique cis-eQTLs (eQTLs located within 50 Kb of the expression probe) and 1924 unique trans-eQTLs (eQTLs farther than 50Kb from the expression probe) from the blood (Supplementary Table S2A and Supplementary Table S3A) and 2,974 unique cis-eQTLs and 87 unique trans-eQTLs from the intestine (Supplementary Table S2B and Supplementary Table S3B) . At the gene level, based on the official microarray annotation, we discovered 5,174 cis-and 1,238 trans-eQTLs from the blood, respectively; and 2,063 cis-and 76 trans-eQTLs from the intestine, respectively (Table 1) .
Results from the two tissues showed a high degree of overlap, with 460% of the intestine genes also reaching significance in whole blood (Figure 2 ). The lower number of eQTLs discovered in intestine as compared with the blood was mainly due to the smaller sample size of unique individuals in the intestine dataset ( Table 1) . The newly mapped gene expression controlling loci (eSNPs henceforth) are enriched in the regulomeDB database 16 (odds ratio; OR = 3.44 and 3.35 for blood and intestine cis-eQTLs, respectively) with similar results observed for trans-eQTLs (Table 1) , indicating their concentration in regulatory regions and further supporting their putative functional relevance.
Within the 149 analyzed blood samples, we quantified the eQTLs effects sizes as quantified the fraction of gene expression variability explained by the eSNP genotype (termed as R 2 ). For the 203 intestine biopsy samples it was not obvious how to quantify R 2 owing to repeated measures from only 54 independent individuals, and we thus omitted them from this specific analysis. Several eQTLs showed a large R 2 . For example, ERAP2 expression (Endoplasmic Reticulum Aminopeptidase 2, which has been previously reported in multiple studies 6, 17 ) was influenced by the cis eSNP rs2927608 in both blood and intestine, with the IBD risk allele associated with higher gene expression in both tissues. The genotype of this locus alone accounted for 74.5% of the total variability of ERAP2 expression in blood. Overall, R 2 was distributed between 8.5 and 74.5% within blood cis-eQTLs, and between 37.6 and 69.7% within blood trans-eQTLs, indicating the powerful effect of these eSNPs on gene expression.
One of the primary utilities of eQTLs is to assign functional relevance to findings from GWAS. We employed different data mining strategies to embed our eQTL results in the context of human diseases and traits in general, and of CD in particular (see Figure 1b) : enrichment for disease-associated loci; remapping of eQTLs within known CD risk loci; Ingenuity Pathway Analysis for biological pathway insights; and finally cell type enrichment analysis of remapped genes controlled by CD risk SNPs. The results of these analyses are reported in the following sections.
Blood and intestine eQTLs are enriched in disease risk loci. To embed our eQTL results in the context of human disease we first surveyed the SNPs in the National Human Genome Research Institute (NHGRI) GWAS catalog [18] [19] [20] as a whole. The NHGRI public catalog maintains a list of GWAS hits (of various diseases including CD) using stringent P value thresholds based on the strict guidelines of replication. We detected significant enrichment for the eQTLs discovered in this study (P value = 6.2e-203; OR = 3.25), indicating that GWAS hits (as a whole regardless of the disease/trait) were more likely to be eQTLs than non-risk associated loci: 8.8% of the NHGRI catalog loci were significant eQTLs in either blood or intestine in our dataset, compared with 2.9% for the rest of the tested genome.
Second, we focused on diseases/traits with at least 90 GWAS association loci documented in NHGRI GWAS catalog (Figure 3a and Supplementary Table S4 ). The rationale of limiting the analysis within diseases/traits with many GWAS hits (i.e., ≥ 90) is to ensure sufficient statistical power in enrichment test. The tests showed that IBD GWAS hits were highly enriched for both intestine and blood (Figure 3a) . In other words, a significant fraction of IBD risk loci were influencing gene expression (i.e., as eQTLs) in blood and intestine tissue. In total, 57 out of 201 IBD risk loci were supported by eQTLs in at least one tissue. As already observed for the entire set of mapped eQTLs, many of these (14 loci) were shared between blood and intestine. In all, 40 IBD risk loci were supported by blood-specific eQTLs, and three loci (rs11741861, associated with ZNF300P1 gene expression; rs12677663, associated with SBSPON gene expression; and rs1728918, associated with 240330_at probeset expression level) were intestine-only eQTLs ( Figure 3 and Supplementary Table S4 ). Furthermore, there was a high ranking of eQTL enrichment in IBD-associated disease traits indicating that blood and intestine are highly relevant tissues for this disease. Some of these eQTL enriched trait categories included growth and development (e.g., metabolite levels, bone mineral density, and height) and inflammatory diseases (e.g. Figure 2 Overlap between SNP-controlled genes in blood and intestine. A large degree of overlap was observed between discovered SNP-controlled genes from blood and intestine tissues. IBD and type-1-diabetes), indicating the role of these two tissue types in these diseases. In contrast, psychiatric and neurological disease GWAS loci were under-present among blood and intestine eQTLs, indicating that these tissues are less relevant to these conditions. It should be noted that the background of enrichment test for each disease/trait (Figure 3a) was the NHGRI catalog SNPs as a whole. As GWAS hits are enriched among eQTLs (regardless of disease type), the individual disease/trait enrichment test and point estimations (i.e., OR) tend to be conservative ( Figure 3a and Supplementary Table  S4 ). But the ranking of the disease traits, which is the main purpose of the analysis, was not affected. Importantly, known IBD GWAS loci were shown as tissuespecific or shared eQTLs (Figure 3b ). For example, SLC22A5 (Solute Carrier Family 22 Member 5) loci act as eQTLs in both blood and intestine, and the genetic control of gene expression follow similar pattern in blood and various sections of intestine (Supplementary Table S4 and Figure 3a) . NOD2 locus was a blood-specific eQTL, where the rs17221417-G allele was associated with lower expression level in blood (Figure 3b ), whereas the rs17221417-NOD2 association was inconsistent among the intestine sections. ZNF300P1 locus was an intestine-specific eQTL, and the eQTL pattern was highly consistent in intestine sections (Figure 3c ), but not in blood.
Supplementary Table S2 presents the genome-wide eQTLs discovery, which is subject to heavy multiple testing penalty and consequently relatively low statistical power. We conducted a secondary eQTL discovery only focus on the known IBD risk loci. By these means, we limited the number of tests and therefore achieved higher statistical power (than genome-wide search). In total, we found that 110 unique genes were influenced by IBD risk loci (Table 2) , and provided empirical evidence of directionality and magnitude of modulation through which IBD risk loci modify disease susceptibility. The GWA studies typically propose genes affected by association loci based on physical location and proximity on the genome. In many cases, several genes are close to the association peak and it is difficult to identify the gene(s) that mediate genetic effect. For example, the Chr17q12 locus showed strong association with IBD (lead SNP rs12946510, P value = 4.00E-38), and several genes (IKZF3, ZPBP2, GSDMB, ORMDL3, GSDMA, etc.) were proposed as genes affected by this variant in this locus. 6 In blood of our CD subjects, we now show that rs12946510 profoundly influences GSDMB (Gasdermin B) gene expression in this locus ( Table 2 ). In total, 10.5% of the GSDMB gene expression variance was explained by this single eSNP. Furthermore GSDMB was linked to other inflammatory diseases (e.g. asthma) by GWAS, 21 and its expression levels were under eQTL control in lung 9 and epithelium. 22 In another unrelated loci we also found evidence for a single eSNP controlling multiple genes. For example, rs1363907 was reported in association with IBD (P value = 6E-13) in GWAS, 6 as upregulating both ERAP2 (eQTL P value = 2.95E-38 in blood Figure 3 eQTLs enrichments for disease-associated loci. (a) We tested the overlap between known and validated disease/trait-associated loci (from the NHGRI GWAS catalog) and expression Quantitative Trait loci discovered from the blood and intestine of anti-TNF-resistant patients. Disease traits were sorted according to odds ratio of enrichment for disease/trait-associated loci within intestine eQTLs. In parentheses, we present the number of overlaps in the following order: number of disease/trait loci overlapping with intestine-specific eQTLs; number of disease/trait loci overlapping with eQTLs shared by blood and intestine; number of disease/trait loci overlapping with bloodspecific eQTLs; total number of loci for the considered disease/trait. The heatmap color indicates the overlap log-odds ratio, with red, white, and blue indicating overlap above, in line with, and below what would be expected by random chance. (b) Intersection between IBD-associated loci (from a genome-wide analysis of the WTCCC dataset) and blood/ intestine eQTLs. Highlighted some shared (green circles), blood-specific (red circle), and intestine-specific (blue circle) eQTL peaks. Table 2 Intersection of blood and intestine eQTLs with GWAS hits and P value = 1.50E-13 in intestine) and LNPEP (eQTL P value = 3.2E-16 in blood but not significant in intestine) through cis-eQTLs (Table 2 ). ERAP2 and LNPEP are both aminopeptidases, which are involved in antigen presentation. ERAP2, a highly conserved, interferon γ inducible gene, 23 is involved in peptide trimming in the endoplasmic reticulum required for major histocompatibility complex class 1 presentation, and has been previously described in other genetic studies of IBD.
Pathway enrichment analysis of genes controlled by CD risk loci in blood and intestine. Whereas the NHGRI GWAS catalog and most publications only report the top signals as in those a passing genome-wide significant threshold of 5e-8, most of the existing GWAS only have moderate statistical power, therefore many true diseaseassociating SNPs may only show a suggestive P value (e.g., P valueo1e-3). Thus, it is generally considered that eQTLs can guide identification of susceptibility genes and active pathways by utilizing a full dataset rather than just the published top hits of GWAS signals. In this paper, we leveraged the full results of large IBD GWAS, 6 filtered by P value ≤ 0.001 (Supplementary Information), and termed these as "IBD SNPs". Importantly, through integrating these "IBD SNPs" with our newly discovered intestine and blood eQTLs (10% false discovery rate) we obtained a list of 96 and 335 genes, respectively, that were controlled by these genetic loci. These blood and intestine genes were subsequently submitted for biological pathway analysis using Ingenuity Pathway Analysis to determine their enrichment in canonical pathways and predicted upstream regulators.
Genes influenced by IBD GWAS SNPs in blood (through eQTLs) were enriched for several canonical pathways: T-cell signaling, antigen presentation, JAK/STAT signaling, interferon response, and pathways related to inositol metabolism (Figure 4a ). Although the pathways enriched in blood and intestine eSNPs were highly overlapping (Figure 4b ), there were also a number of pathways that showed tissue-specific enrichment. Enrichment in common pathways between blood and intestine are driven by shared eSNPs in human leukocyte antigen and JAK/STAT signaling genes, whereas pathways uniquely enriched in blood eSNPs included protein ubiquitination, Systemic Lupus Erythematosis signaling and PPARa/ RXRa activation (Supplementary Tables S6 and S7) .
Compared with blood eSNPs, intestine eSNPs gave rise to fewer enriched pathways with less coverage (Supplementary  Table S6 vs. Supplementary Table S7 ), therefore we have focused on the blood eSNPs for upstream regulator analysis. In this analysis Ingenuity Pathway Analysis software predicts for any given gene list, the potential upstream regulators or transcription factors of these genes, based on their databases containing literature supported downstream targets of genes Because our submitted gene list did not include information on changes in gene expression, the predicted upstream regulators do not have an associated likelihood of being activated or inhibited. For blood eSNPs, the top predicted upstream regulators included IFNγ, lipopolysaccharide, and genes involved in antigen presentation and T-cell signaling (Supplementary Table S11-A). Interestingly, the top predicted upstream master transcription factors included the forkhead ↑ denotes the GWAS risk allele increases expression level of the eQTL gene; ↓ denotes the GWAS risk allele decreases the expression level of the eQTL gene; and NS denotes no significant eQTLs were detected in our dataset. Novel eGenes with respect to previous published findings from IBD, UC and FAP patients are highlighted in bold.
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(Fox) family members FOXD1 and FOXJ1, both of which have been predicted to have roles in inhibiting inflammation through negative regulation of NFAT (nuclear factor of activated T cells) and NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) gene pathways (Supplementary Table S11-B) .
Cell type-specific enrichment of genes influenced by eQTLs. Given that blood and intestinal mRNA expression analysis is the summation of expression of mRNA's from potentially multiple cell types within a particular tissue type, we attempted to further refine our eQTL analysis by determining the cell types most likely expressing the genes associated with IBD SNPs. To do this we took advantage of the (GEB) Gene Expression Barcode database, which provides reliable absolute measures of expression for most annotated genes for over 100 human tissue types, including diseased tissue. To determine cell types associated with genes with eSNPs we retrieved the GEB 3.0 dataset, which assigns each probeset targeting a gene, to the tissues and cell types where that probeset is expressed. 24 Note that there can be multiple probesets targeting a single gene. We mapped all eSNP expression probesets with IBD GWAS P valueo1e-3 to their corresponding cell types and gene labels. The summary of all eSNP probesets according to GEB classification and cell type-specificity is shown in Table 3 . Blood eSNP probesets showed enrichment in 24 cell types (Supplementary Methods), whereas intestine eSNP probesets did not show significant enrichment (e-valueo0.05) in any cell type, possibility owing to the smaller number of intestine eSNPs than blood and consequently lower statistical power. Figure 5 shows the mapping of blood eSNP genes to the 24 significantly enriched cell types. Blood eSNP genes showed strongest enrichment in T cells, neutrophils, monocytes, and natural killer cells ( Figure 5 ). Of note, the enriched T-cell subsets are specific to naive T cells, regulatory T cells and CD161+CD8 T cells. Genetic perturbation of pathways associated with regulatory T-cell development or cytokines produced by regulatory T cells are strongly implicated in IBD pathogenesis in murine models of colitis, monogenic very early-onset IBD and GWAS loci identified in adult-onset IBD patients 25, 26 thus supporting our observations. Interestingly, CD161+CD8 T cells have a phenotype consistent with mucosal-associated invariant T cells, which have semi-invariant T-cell receptors that recognize bacterial metabolites 27, 28 and have been recently proposed to have Table S6 and Supplementary Table S7 ).
a role in IBD, though whether protective or pathological is still unclear.
DISCUSSION
In this paper, we report two key results. 1 A systematic identification of a large number of eQTLs in two CD-related tissues the blood and intestine from anti-TN-resistant Crohn's patients and 2 the novel characterization that many known IBD GWAS loci were actually eQTLs in blood and intestine. Based on empirical evidence, our approach elucidates a large number of genes driven by IBD loci, which potentially mediate the disease etiology.
Both sample availability and tissue relevance have been taken into account when designing this eQTL study. Although a much smaller number of subjects was available for the study of the intestine limiting power to detect association, the intestine-derived eQTLs, location of disease manifestation, proved crucial to orient the disease role of the GWAS hits, which were otherwise unsupported by the whole blood data. Our results indicate that the analysis of tissues more directly involved in a disease (e.g., the intestine of Crohn's patients) can highlight pathways that would not be otherwise detected in different tissues, even if bigger sample sizes were available. For instance, in Supplementary Tables S6 and S7 we show pathways that are enriched in either blood or intestine, but not in both. This can possibly be due to that disease mechanisms are not active in all tissues.
In the current study, we utilized blood and intestine tissue samples 15 to systematically discover eQTLs, and further related the eQTLs to IBD GWAS loci. In agreement with previous findings, [29] [30] [31] [32] we found that a large proportion of eQTLs are shared across blood and intestine. Specifically, we found that 460% of the intestine SNP-controlled genes were also influenced by eQTLs in blood. Given the stringent cutoff we imposed on such comparison (i.e., we required eQTLs to pass 10% false discovery rate in both tissues), this is a conservative estimate of the amount of sharing between the two tissues, and a relaxation of the significance threshold would likely result in an even higher overlap. 32 The high overlap between the two tissues is further confirmed within the disease/trait-associated SNPs reported in the NHGRI catalog, where the number of GWAS peaks shared between intestine and blood is higher than what would be expected by random chance alone. This finding holds true across all the traits we surveyed (Figure 3a) , however we also replicated and discovered a large number of blood-and intestine-specific eQTLs underlying disease GWAS hits, pointing to tissuespecific roles of an IBD genetic variant. We also observe a few eQTLs we discovered in this study overlap with previously reported eQTLs by Kabakchiev et al. 17 and by Singh T et al.
33
More specifically, we compared our newly discovered eQTLs with previously published eQTLs from a number of tissues and from subjects of different disease conditions (Supplementary Table S10 ). Besides the already highlighted high overlap between intestine and whole-blood eQTLs of the present study, we observed a particularly high overlap with previously published ileum and rectum eQTLs (odds ratios = 3.09 and 2.93, respectively) obtained from independent populations composed of UC 17 and Familial Adenomatous Polyposis 17 patients, as well as IBD and normal controls.
33 Surprisingly, our whole-blood eQTLs showed a much higher degree of overlap with ileum and rectum eQTLs from independent IBD cohorts (odds ratios = 1.54 and 1.70, respectively) than with whole blood eQTLs obtained from the meta-analysis of generically healthy subjects (odds ratio = 1.19). This finding suggests that, to some extent, the selection of subjects with the right disease context might be more Figure 5 Cell type enrichment of blood eSNPs. Heatmap displaying clustering of cell types enriched in blood eSNPs (enrichment P value o0.05); cell types on y axis and genes driving enrichment on the x axis. Dark red squares indicate a gene is present in the corresponding pathway listed to the right.
important than or as important as the collection of relevant tissues in the design of an eQTL study. It should be noted that tissue-level eQTLs in fact investigate expression level of a mixture of cell types. For example, intestine tissue of IBD subjects contains many type of cells, including various kinds of immune cells, which presumable in part are infiltrating via the blood. Therefore, the blood tissue and intestine tissue of Crohn subjects have shared cell types, and the eQTLs detected in these two tissues were somewhat overlapping.
It is important to highlight that our study cohort differs from a generic cohort of Crohn patients in that they were all resistant to anti-TNF therapy. This might have impacted our findings in at least two ways: (1) the genetic background of anti-TNF resistant CD patients might be slightly different from that of anti-TNF responders; and (2) exposure to anti-TNF therapy before the collection of blood and intestine samples, if unsuccessful in treating CD itself, might well have impacted the microbiome of the patients, thus revealing expression patterns not otherwise found in a more general patients' population.
Besides observing statistically significant overlap of eQTLs discoveries from different tissues from a same set of subjects (i.e., between intestine and blood eQTLs in the present study) and between subjects of different disease conditions (e.g., Supplementary Table S10), we also observed some degree of heterogeneity across different intestine sections within our cohort. Even though our small sample size does not allow us to report statistically significant differences across intestine sections in a genome-wide survey, we can report sectionspecific association patterns when we zoom on specific loci of interest. One such example is the IBD risk locus NOD2 (rs17221417, Figure 6b ), for which terminal ileum and rectum display the same pattern of expression observed in whole blood, whereas ascending, transverse, descending, and sigmoid colon display a rather unclear, if opposite, direction of this same effect. This inconsistent association pattern of the risk locus with NOD2 gene expression allowed as to report a significant eQTL from the blood only, but not from the pooled intestine data analysis.
As in complex diseases, multiple pathways and gene networks are altered in IBD. We identified many genes relevant to IBD in the analysis of intersection between eQTLs and published association signals from GWAS studies focusing on IBD, UC and Crohn's ( Table 2 ). The large number of biologically plausible findings indicate the eQTLs as powerful tools to interpret and dissect GWAS signals. In the vast majority of the genes listed in Table 2 , the direction of transcription regulation (i.e., up-or downregulation) caused by GWAS SNPs on the genes, agree with our current understanding of IBD molecular etiology. To help the reader interpret our observations we have organized the genes influenced by IBD GWAS hits (mediated by blood and intestine eQTLs) by functional categories and discussed their potential relevance below. These types of insights are what we hope gives momentum to the task of unraveling the underlying causes of IBD and then how one could potentially intervene therapeutically.
Epithelial barrier. Increased levels of ADCY3 (Adenylate Cyclase 3) in intestine and blood eQTLs 34 have been linked through activation of the CREB pathway to upregulation of the levels and activity of MMP2 and MMP9 matrix metalloproteases involved in tissue re-modeling and wound repair, which are known effectors of tissue damage in IBD. 35 Another eQTL with an intestinal epithelial manifestation is TSPAN14 (tetraspanin 14), whose gene expression is controlled by an IBD GWAS SNP (rs6586030) in both blood and intestine (Table 2) . While also expressed in immune cells, TSPAN14 has an intestinal epithelial role as a positive regulator of ligand induced ADAM10-mediated Notch1 activation. ADAM10 is a sheddase expressed on the surface of intestinal epithelial cells and is important for intestinal epithelial cell lineage specification and crypt cell columnar cell maintenance. This eQTL, resulting in a decrease in transcript in IBD, could contribute to epithelial barrier and restitution defects. [36] [37] [38] Metabolism. In accordance with the analysis of the highest trait enrichment in IBD for NHGRI GWAS, we identified several eQTLs involved in metabolism. We reproduced, from previous reports, (Repnik and Potocnik, 2011), a significant cis-eQTL for the solute carrier family 22 member 5 (SLC22A5) in both the blood and intestine in our Crohn's cohort. The T allele, which is associated with increased risk of CD/IBD was found to associate with decreased expression of SLC22A5. This decrease in expression in the intestine was also seen when each of the regions sampled were calculated separately (see Figure 6c ). Similar observations were seen in a Slovenian cohort of refractory CD patients whereby lower expression of SLC22A5 gene was associated with diseasesusceptible genotypes for two IBD disease-associated SNPs. SLC22A5 encodes a polyspecific organic cation transporter and has a high affinity for carnitine. 39 Autosomal recessive mutations cause primary carnitine deficiency, which leads to a defect in mitochondrial fatty acid oxidation. Furthermore, experimental validation in SLC22A5 knockout mice have pointed to expansion of activated CD4 T cells and increased enterocyte apoptosis in the small intestine. Lower levels of DLD (dihydrolipoamide dehydrogenase), another GWAS eQTL, can result in metabolic disturbances. DLD is the third subunit of the alpha-ketoglutarate dehydrogenase complex, which catalyses the decarboxylation of alpha-ketoglutarate into succinyl-coenzyme A in the Krebs cycle. This can lead to accumulation of pyruvate and branched-chain amino acids in plasma and branched-chain alpha-ketoacids in urine. 40 DLD has also been reported in lactic acidosis affecting carbohydrate fermentation, which has been implicated in ischemic colitis and short bowel syndrome. [40] [41] [42] [43] Monocytes/mcrophages. Several blood and intestine eQTLs have been identified as having specific roles in monocyte and macrophage function such as differentiation, polarization, and migration. LST1 is upregulated by Crohns GWAS risk alleles and has been reported as being a pro inflammatory marker expressed in the colon of IBD patients where its expression has a role in intestinal epithelial cells, monocyte differentiation, and nanotube formation. 44, 45 IRF5, expressed in macrophages as well as T cells, is frequently upregulated by inflammatory stimuli in autoimmunity. We found various probesets of this gene were either up-or downregulated by UC GWAS risk alleles (Table 2) , suggesting different behavior of IRF5 splicing isoforms (Supplementary Figure 6 Tissue specificity of IBD-associated eSNPs. Some example of eSNPs that were previously reported to be associated with IBD, with different degree of tissue specificity in their gene expression signal. Genotype on the horizontal axis, mean-centered expression levels on the vertical axis. (a) Polymorphism rs11741861 shows a significant association with ZNF300P1 mRNA levels in all the intestine sections, but not in the blood; (b) polymorphism rs17221417 shows different effects on NOD2 in different tissues; (c) polymorphism rs2188962 controls SLC22A5 expression uniformly and with a similar effect across different tissues.
Blood and Intestine eQTLs Underlying IBD Risk Loci Di Narzo et al. Table S9 ). IRF5 is a marker for M1 macrophages and leads to production of IL-12 p40, IL-12 p35, and IL-23p19 while repressing IL-10. These macrophages create an environment conducive for a potent T-helper type-1 T(H)1-T(H)17 response, 46 however, a downregulated variant may skew macrophage polarization to an M2 phenotype, which has been associated with ulcerative colitis.
Several identified GWAS enriched eQTLs are involved in migration. AIF1 is upregulated by Crohn GWAS risk allele, and has been shown to increase chemokine expression in monocytes in addition to having a putative role in T cells 47 (24796669). Increased SKAP2 transcription, caused by the UC GWAS risk allele (Table 2) , is involved in cytoskeletal re-arrangement and macrophage migration for integrin induced responses. Other eQTLs are less studied, such as TM9SF4, which is upregulated by IBD GWAS risk allele and has a conserved immune function in adhesion and phagocytosis in drosophila. 48 Eosinophils. GSDMB and ORMDL3 are controlled by both blood and intestine eQTLs, and are also associated with UC and Crohns in GWAS studies. This gene locus has been linked to alterations in eosinophillic number and hyperinflammation in asthma. 49, 50 An intestine-specific risk eQTL allele downregulates gene expression (Table 2) . ITLN1 is also a serum biomarker for disease activity with lower levels found in IBD patients. 51 Interferon response. As seen through the enrichment in the JAK STAT pathway of eQTLs of this TNF refractory population, genetic susceptibility in cytokine signaling can lead to dysregulated immune homeostasis in the intestine. EMSY (c11orf30), downregulated by IBD GWAS risk allele, is a transcriptional repressor in the PI3K/AKT pathway of the interferon response. Other interferon-responsive eQTLs are IRF1, whose upregulation has also been reported in IBD 52 and TNFSF15, an eQTL which induces IFNγ and IL17 through synergizing with IL18 and IL23 and can be both activated and repressed by NF-κB. 53 NF-κB. Both the blood-specific eQTLs pathway enrichment and predicted regulators involve ubiquitination and NF-κB. CUL2 is part of a ubiquitin ligase complex involved in modulating the NF-KB pathway through proteosomal degradation of sub units. 54, 55 DNMT3B, a DNA methyl transferase, is recruited by transcription factors such as NF-KB and TRAF1. Less methylation, resulting from downregulation of DNMT3B by the IBD risk allele could lead to more activation of NF-KB and TRAF1, which have been reported as being upregulated in IBD. 56, 57 UBE2L3 is involved in regulating TNFα induced linear ubiquitination of NEMO, potentially having a critical role in assembling and orchestrating the componentry of the TNFR1 signaling platform. 58, 59 Whereas, APEH, a negative effector of proteasome activity, 60 is downregulated by UC risk allele in intestine, potentially involving modulation of the NF-KB pathway.
Autophagy, inflammasome, and endoplasmic reticulum stress. IPMK that is upregulated by a risk allele identified in IBD and Crohn GWAS is involved in induction of early response genes in serum through stabilization of mechanistic target of rapamycin while acting as a co-activator for CREB-binding protein/E1A-binding protein p300. 61 The expression level of death-associated protein was profoundly downregulated by the UC risk allele in both blood and intestine. DAP was reported to be linked to TGFB-induced apoptosis (transforming growth factor, beta 1) through SMAD-mediated expression and is a putative regulator in the induction of autophagy. 62 Tu translation elongation factor also has a role in enhancement of autophagy and inhibition of the type I interferon response. 63 PRKCB, influenced by its blood expressed eQTL, is a negative regulator of autophagy and the mitochondrial energy supply. 64 MAPRE1, upregulated by IBD risk allele in blood, has a role in autophagymediated induction of the AIM1 inflammasome leading to secretion of IL1B.
65 CARD9 is also involved in inflammasome activation, acting as an adapter that mediates protein-protein interactions, interacts with NOD2 and is associated with antifungal response, the IL23R/IL17 pathway, and epithelial restitution. [66] [67] [68] CARD9, include variants both up-and downregulated as blood eQTLs and has been reported as being differentially methylated between IBD cases and controls. 69 CCDC101, showed as the only gene to be influenced by rs26528-C (1.50E-11), was profoundly downregulated by the IBD risk allele (rs26528-C), a histone acetyltransferase important for response to endoplasmic reticulum stress. 70 Lymphocytes. Through our eQTL enrichment analysis in cellular specific gene expression signatures, genes related to T-cell function and T-regulatory cells, in particular, were among the top hits in blood in Crohn's. CD244 (2B4), a non MHC-binding inhibitory receptor on activated NK and CD8 memory cells interacts with CD48 and has a role in regulating tolerance. 71 CD6 is involved with TCR signaling 72 and T regs are characterized by low CD6 expression. 73 NDFIP1, potentially a protective allele, is upregulated by its IBD GWAS risk allele in the blood where it acts as an adapter for ubiquitin ligase in induction of peripheral tolerance. NDFIP1 is activated by TGFB to suppress IL4 in inducible T regs. 74, 75 Another blood-specific eQTL includes ZNF300, which is downregulated by Crohn risk allele and is involved in activating the IL2βR expressed highly on T-regulatory cells. 76 Other identified eQTLs were involved in T-cell skewing. For example, FOSL2 is an AP1 transcription factor, which is a putative regulator of plasticity and repressor of TH17 cells. In in vitro experiments, FOSL2 overexpression was shown to decrease the number of IL17A producing T cells, whereas FOSL2 deficiency enabled IFNγ production in Th17 and Th2 cell cultures when Th17 cells were subsequently exposed to Th1-skewing conditions. 77, 78 CCDC88B is a regulator of T-cell function, 79 and is upregulated in Crohn's and can lead to excessive CD4+ and CD8+ activation and altered IL-12 and TNFα production. For B cell-related eQTLs, downregulation of ZFP36L1 is the directional consequence of IBD RISK allele rs194749C, and has been reported as negatively regulating plasma cell differentiation by targeting BLIMP1, of which lower levels could lead to enhanced antibody production. 80 In summary, we systematically characterized eQTL architecture in two IBD relevant tissues (blood and intestine), and identified genes influenced by IBD GWAS loci known to date. Our approach revealed a large number of genes driven by IBD loci which potentially mediate the disease etiology. For example, rs26528-C was strongly associated with IBD (P = 1.00E-21), 6 and RABEP2, IL27, EIF3C, SULT1A1, SULT1A2, NUPR1 were proposed as underlying genes. 6 Our results demonstrated eQTLs as a powerful approach in interpreting genetic study results. We found 4200 eQTLs on known IBD GWAS loci (Table 2) , and informed 109 out of 372 IBD GWAS SNPs documented in NHGRI catalog. Many of the genes mapped to these eQTLs have experimentally validated roles in cell types contributing to intestinal inflammation. These findings reflect our most up-to-date and comprehensive understanding of transcriptome regulation of IBD GWAS, and will serve as a valuable resource in further dissecting the molecular basis of this disorder.
